Johnson & Johnson

JNJ

US4781601046

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 03:38:13 2024-10-15 pm EDT			5-day change	1st Jan Change
163.86 ^USD	+1.40%		+2.61%	+4.54%

09:27pm	Trending : Johnson & Johnson Posts Higher-Than-Expected Sales	DJ
08:31pm	Stifel Raises Johnson & Johnson's Price Target to $170 From $160	MT

J&J to invest more than $2 billion in new manufacturing facility

October 01, 2024 at 02:08 pm EDT

(Reuters) - Johnson & Johnson said on Tuesday it will invest more than $2 billion to build a new manufacturing facility at Wilson, North Carolina.

(Reporting by Sriparna Roy in Bengaluru; Editing by Leroy Leo)

Latest news about Johnson & Johnson

Trending : Johnson & Johnson Posts Higher-Than-Expected Sales	03:27pm	DJ
Stifel Raises Johnson & Johnson's Price Target to $170 From $160	02:31pm	MT
Sector Update: Health Care Stocks Retreat Tuesday Afternoon	02:04pm	MT
J&J CFO Wolk on Product Pipeline, Strategy, Talc Lawsuit	12:31pm	MT
Top Midday Stories: UnitedHealth Narrows Full-Year Earnings Outlook; Nvidia, AMD May Face Country-Specific Export Caps on AI Chips	11:45am	MT
J&J: positive results from phase 2/3 study	11:20am	CF
Johnson & Johnson Lowers Full-Year Earnings Guidance Despite Third-Quarter Beat	10:21am	MT
Genmab's Global Net Trade Sales for Multiple Myeloma Treatment Hits $3 Billion in Q3	09:21am	MT
Sector Update: Health Care Stocks Flat to Lower Pre-Bell Tuesday	09:20am	MT
Johnson & Johnson Reports Positive Phase 2/3 Study Results for Nipocalimab in Myasthenia Gravis Adolescents	09:06am	MT
Mixed Corporate Earnings Stifle US Equity Futures Pre-Bell	08:51am	MT
Silicon is the new black	08:47am
Johnson & Johnson, Q3 2024 Earnings Call, Oct 15, 2024	08:30am
Traders Digest Key Earnings as US Equity Futures Tread Water Pre-Bell	08:20am	MT
Johnson & Johnson Announces Positive Results from the Phase 2/3 Vibrance-MG Study of Nipocalimab	08:00am	CI
J&J: EPS targets lowered for 2024	07:51am	CF
Stocks Mostly Down Pre-Bell Ahead of Key Earnings; Asia Churns, Europe Falls	06:53am	MT
Johnson & Johnson Fiscal Q3 Adjusted Net Earnings Fall, Sales Rise; Full-Year Adjusted EPS Guidance Lowered	06:52am	MT
Genmab: Darzalex sales amounted to over $3 billion in Q3	06:31am	FW
Johnson & Johnson Announces Dividend for Fourth Quarter of 2024, Payable on December 10, 2024	06:25am	CI
Earnings Flash (JNJ) JOHNSON & JOHNSON Reports Q3 Adjusted EPS $2.42	06:24am	MT
Earnings Flash (JNJ) JOHNSON & JOHNSON Reports Q3 Revenue $22.47B	06:23am	MT
Earnings Flash (JNJ) JOHNSON & JOHNSON Reports Q3 EPS $2.42	06:23am	MT
J&J lifts profit and sales forecasts, beats Wall Street expectations	06:22am	RE
Johnson & Johnson Reports Earnings Results for the Third Quarter and Nine Months Ended September 29, 2024	06:20am	CI

Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (64.3%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (35.7%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals; At the end of 2023, Johnson & Johnson has 61 manufacturing facilities located in the United States (23), North America (5), Europe (20), Africa and Asia/Pacific (13). The United States accounts for 54.5% of net sales.

Employees

131,900

Sector

Pharmaceuticals

Calendar

06:45am - Q3 2024 Earnings Release

More about the company